BURLINGAME, Calif., August 19 /PRNewswire-FirstCall/ -- Urigen Pharmaceuticals, Inc. (OTC Bulletin Board: URGP, http://www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, today announced the U.S. Patent and Trademark Office has issued the first patent for the use of URG101, an investigational, bladder instillation treatment for Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC). Patent number US 7,414,039 broadly covers the use of the URG101 product in the treatment of PBS/IC. The term of the patent extends into 2025.
"Not only does this patent establish protection for the use of URG101 in Painful Bladder Syndrome and Interstitial Cystitis; it also validates the excellent intellectual property guidance provided by Tom Jurgensen, JD of Catalyst Law and Stephen Reiter, PhD, JD of Foley & Lardner," stated William J. Garner, MD, President and CEO of Urigen. "We will continue to execute our intellectual property strategy to strengthen our proprietary position in the field of PBS/IC."
Urigen has announced positive results from a Phase 2 study of URG101. The study was a multi-center, double-blind, placebo-controlled, crossover trial. Findings from the study included:
-- Primary Endpoint -- Improvement in Average Daytime Pain (p=0.03).
-- Secondary Endpoints -- Improvement in Daytime Urgency (p=0.03) and Total Symptom Score (p=0.03). In addition, patients reported improved symptom relief with URG101 as measured by PORIS (p=0.01).
URG101 is a pharmaceutical treatment for Painful Bladder Syndrome/Interstitial Cystitis that is instilled into the bladder. URG101 works with lidocaine reducing the sensations of pain, urge and muscle spasms and heparin, a glycosaminoglycan, coating the bladder wall thus augmenting the natural heparinoids.
About Painful Bladder Syndrome/Interstitial Cystitis (PBS)
Painful Bladder Syndrome/Interstitial Cystitis is a recognized medical condition with increased frequency of diagnosis. PBS/IC is characterized by bladder pain, urinary urgency and nocturia where few IC treatments exist and no approved therapies are available for PBS. Today, there are an estimated 10.5 million women and men in North America who suffer from PBS/IC.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets Painful Bladder Syndrome/Interstitial Cystitis, which affects approximately 10.5 million men and women in North America. URG301 targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen's website at http://www.urigen.com.
This press release may contain forward-looking statements. In some
cases, you can identify forward-looking statements by terminology such as
"may," "will," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential" or "continue," the negative of such
terms, or other comparable terminology. These statements are only
predictions. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, such statements should not be
regarded as a representation by the Company, or any other person, that such
forward-looking statements will be achieved. We undertake no duty to update
any of the forward-looking statements, whether as a result of new
information, future events, or otherwise. In light of the foregoing,
readers are cautioned not to place undue reliance on such forward-looking
statements. For further risk factors associated with our Company, please
review our SEC filings.
Urigen Pharmaceuticals, Inc.
Martin E. Shmagin
Chief Financial Officer
|SOURCE Urigen Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved